MedTrace Logo

Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)

NCT02314403 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-10-25

Study results available
· View outcomes & findings →

Summary

This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system

Conditions

  • Kidney Failure, Chronic
  • Renal Insufficiency

Interventions

DRUG

Belatacept

A selective T-cell (lymphocyte) costimulation blocker

DRUG

ATG

A T-Cell Depleting Agent

DRUG

Rituximab

B-Cell Depleting Agent

RADIATION

Total Body Irradiation

RADIATION

Thymic Irradiation

PROCEDURE

Combined Bone Marrow/Kidney Transplantation

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Tatsuo Kawai, MD PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2021-03-31
Completion
2021-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02314403 on ClinicalTrials.gov